

Press Release

ProStrakan Announces Board Changes

Galashiels, UK. 11th November 2013 – ProStrakan Group plc, the UK-based specialty pharmaceutical company, which is a subsidiary of Kyowa Hakko Kirin Co., Ltd., the Japan-based global specialty pharmaceutical company, announces the resignation of Chairman, Peter Allen, and non-executive Director, Dr Michael Asbury, and the appointment of Dr John Brown CBE FRSE as Chairman.

The board changes follow the successful integration of ProStrakan into the Kyowa Hakko Kirin business following its acquisition in 2011. Peter Allen and Dr Michael Asbury will leave the ProStrakan board on 31st December 2013, with Dr John Brown's appointment taking effect from 1st January 2014.

Commenting on the board changes, Dr Tom Stratford, Chief Executive of ProStrakan, said:

“Peter and Mike have each been long-standing members of the ProStrakan board and, during their time with us, ProStrakan has grown significantly and transitioned from being a small independent company into an important part of Kyowa Hakko Kirin. I would like to thank them personally for their support and, on behalf of our other Board members, for their commitment and contribution over the years.”

Dr John Brown brings with him a wealth of pharmaceutical expertise. He is currently Chairman of the Cell Therapy Catapult and CXR Biosciences Ltd, and senior non-executive Director of Vectura Group plc. He was formerly Chairman of BTG plc, Axis-Shield plc and prior to that, Chief Executive of Acambis plc.

In the public sector John co-chairs the Life Sciences Industry Advisory Board for the Scottish Government and is Chairman of the Roslin Foundation.

Commenting on John's appointment, Tom Stratford said:

"We are thrilled to have been able to attract someone with John's credentials as our new Chairman. John brings with him a wealth of experience of the life sciences industry and we look forward to the guidance and advice that he will undoubtedly bring to the ProStrakan board. On behalf of his fellow board members, I welcome John to the ProStrakan board."

Ends

Further enquiries:

Callum Spreng
ProStrakan

Tel: 0141 548 5191
Mob: 07803 970103
Email: callum@sprengandco.com

About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. ProStrakan is a subsidiary of Kyowa Hako Kirin Co., Ltd., the Japan-based global specialty pharmaceutical company. ProStrakan's head office is located in Galashiels in Scotland. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries. You can learn more about the business at: www.prostrakan.com